产品说明书
SC-560
 |
同义名 : | - |
| CAS号 : | 188817-13-2 | |
| 货号 : | A252197 | |
| 分子式 : | C17H12ClF3N2O | |
| 纯度 : | 99%+ | |
| 分子量 : | 352.738 | |
| MDL号 : | MFCD02179214 | |
| 存储条件： |
粉末 Sealed in dry,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(297.67 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | The cyclooxygenase (COX) enzymes (COX-1 and COX-2) catalyze the bis-oxygenation of free arachidonic acid to prostaglandin (PG) H2, the precursor of other PGs and thromboxane (Tx). SC-560 is a selective COX-1 inhibitor with an IC50 value of 9 nM. It shows much less inhibitory potency against COX-2 with an IC50 value of 6.3 μM[3]. SC-560 decreased COX-1-dependent TxB2 production in human platelets with an IC50 value of 2.5 nM. It also reduced COX-2-dependent PGE2 synthesis in LPS-stimulated human monocytes with an IC50 value of 1.8 nM[4]. Oral administration of SC-560 (10 or 30 mg/kg) one hour before the whole blood assay inhibited ionophore-stimulated TxB2 production in rats. Oral dosing with SC-560 (0.1-100 mg/kg) blocked the production of TxB2 in a concentration-dependent manner in rat inflamed skin. SC-560 at 100 mg/kg showed 40% inhibition on PGE2 production in LPS-induced rat air pouch. It also efficiently inhibited PGE2 synthesis in stomach mucosa with an ED50 value of 0.2 mg/kg. However, 30 mg/kg SC-560 exhibited no significant effect on the onset of edema or hyperalgesia[3]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.83mL 0.57mL 0.28mL |
14.17mL 2.83mL 1.42mL |
28.35mL 5.67mL 2.83mL |
| 参考文献 |
|---|